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Abstract
Background: The World Health Organization recommends all countries consider screening for H. pylori to prevent
gastric cancer. We therefore aimed to estimate the cost-effectiveness of a H. pylori serology-based screening
program in New Zealand, a country that includes population groups with relatively high gastric cancer rates.
Methods: A Markov model was developed using life-tables and morbidity data from a national burden of disease
study. The modelled screening program reduced the incidence of non-cardia gastric cancer attributable to H. pylori,
if infection was identified by serology screening, and for the population expected to be reached by the screening
program. A health system perspective was taken and detailed individual-level costing data was used.
Results: For adults aged 25–69 years old, nation-wide screening for H. pylori was found to have an incremental cost
of US$196 million (95% uncertainty interval [95% UI]: $182–$211 million) with health gains of 14,200 QALYs (95% UI:
5,100–26,300). Cost per QALY gained was US$16,500 ($7,600–$38,400) in the total population and 17% (6%-29%) of
future gastric cancer cases could be averted with lifetime follow-up. A targeted screening program for Māori only
(indigenous population), was more cost-effective at US$8,000 ($3,800–$18,500) per QALY.
Conclusions: This modeling study found that H. pylori screening was likely to be cost-effective in this high-income
country, particularly for the indigenous population. While further research is needed to help clarify the precise
benefits, costs and adverse effects of such screening programs, there seems a reasonable case for policy-makers
to give pilot programs consideration, particularly for any population groups with relatively elevated rates of
gastric cancer.
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Background
Helicobacter pylori is an important contributor to gastric
cancer incidence [1]. Globally, the treatment of H. pylori
has tended to focus on people presenting to medical
attention with peptic ulcers and indigestion (dyspepsia).
A recent Cochrane systematic review provides evidence
that treating people with H. pylori infection reduces their
subsequent risk of gastric cancer by one- third (95% CI:
0.46-0.95) [2]. In addition to treating H. pylori symptom-
atic individuals, there has been international interest in
using H. pylori testing to screen asymptomatic individuals
in order to prevent gastric cancer from developing.
For example, the Asia–Pacific consensus guidelines for
H. pylori infection recommend screening and treating
H. pylori infection in communities with high incidence
of gastric cancer incidence (20+ per 100,000 popula-
tion) [3]. Targeted screening has been recommended
in some high-income countries for people who are
asymptomatic and at high risk, such as having an eth-
nicity or geographic background associated with a
high risk of gastric cancer (e.g. Asia-Pacific country of
origin) [4]. The International Agency for Research on
Cancer (IARC) and the World Health Organization
(WHO) recommends that all countries assess the
current and future human and economic impacts of
gastric cancer and of the potential value of prevention
strategies [5].
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In addition to other important social values (such as
equity), intervention cost-effectiveness is an important
consideration in the prioritization and funding of health
services. Ten or more cost-effectiveness evaluations for
H. pylori screening, such as serology testing, have been
published from both high and low gastric cancer inci-
dence countries including China, Taiwan, Singapore,
United States, Canada and the United Kingdom. All
evaluations found that H. pylori screening and treatment
was cost-effective, given country-specific willingness-to-
pay thresholds [5]. The models tended however to have
important limitations [5] including: (i) not using meta-
analysis effect sizes for H. pylori treatment [2, 6]
(although some model estimates were similar to meta-
analyses estimates [7–10] and had similar uncertainty
[7, 8]); (ii) all but two [9, 11] modelling studies were
based on life-years-saved rather than quality adjusted
life years (QALYs); (iii) few studies [11–13] conducted a
probabilistic analysis to evaluate the uncertainty in the
data modeled; (iv) harmful effects of treatment were
generally not considered; and (v) there were no data on
low-income countries. This paper aims to address the
first four of these limitations.
New Zealand is an ideal high-income country for such
a case study given the good quality national datasets that
support modeling the cost-effectiveness of a H. pylori
screening program. The age-standardized incidence of
gastric cancer for New Zealand in 2011 was 8.0 for men
and 4.3 per 100,000 for women and incidence in Māori
was 18.6 for men and 14.9 per 100,000 for women
(WHO World Standard Population, all ages). Gastric
cancer demonstrates one of the greatest ethnic inequal-
ities of any cancer site in New Zealand being 2.48 times
higher for Māori (indigenous population) and 2.64 times
higher for Pacific peoples compared to NZ European
(averaged over 1981-2004) [14]. H. pylori infection is
likely the greatest contributor to those inequalities [15].
We therefore undertook an assessment of the cost-
effectiveness of a H. pylori population screening program
in New Zealand. The indigenous Māori population was
selected to examine the relative cost-effectiveness of
screening for a group with higher H. pylori infection
prevalence and gastric cancer incidence. This selection
was appropriate given excellent ethnicity data for Māori
in New Zealand, and the New Zealand Government’s
treaty and ethical obligations to protect indigenous
health.
Methods
We developed a Markov macrosimulation model to evalu-
ate cost-effectiveness of a H. pylori screening program in
New Zealand in 2011 compared with current medical
practice. A total population screening program for 25-69
year olds was compared with a targeted screening pro-
gram for Māori 25-69 years old.
Model overview
The Markov model consisted of states including: healthy,
gastric cancer, death from gastric cancer and death from
other causes (Fig. 1). We did not explicitly model states
of H. pylori infection and pre-cancer but instead aimed
to have a simple model structure and ensure that transi-
tion probabilities ‘captured’ different H. pylori prevalence
in population groups.
Intervention and comparator definition
The modeled screening programs comprised a serology
test to screen for H. pylori in healthy individuals, eradica-
tion treatment with antibiotics from a primary care doctor
if required, a fecal antigen test of cure (retest) and second
- line treatment if required. The recommended first-line
eradication was triple therapy (omeprazole 20 mg, amoxi-
cillin 1 g and clarithromycin 500 mg twice daily for seven
days [16]). Second-line eradication was quadruple therapy
[16] and this was not followed by a retest. We assumed
that all individuals testing positive would be treated.
Similar to many other cost-utility analyses [7–11, 13, 17–19],
we adopted the H. pylori serology for the screening test in
the main results because of its feasibility, acceptability and
affordability. The alternative fecal antigen screening test is
a test of active infection, however the test costs more than
serology, requires a sample to be delivered promptly to
the laboratory and requires patients to stop taking
omeprazole, antibiotics and bismuth (OAC) for two to
four weeks prior to the test, which is likely to be more
problematic for participants. However, we present key
results and uncertainty for fecal antigen-based screen-
ing in a probabilistic sensitivity analysis. Fecal antigen
screening costs were adjusted to reflect differences in the
laboratory cost and the fewer positive tests expected, by
adopting a screening study finding from Japan, where fecal
antigen had consistently 8% fewer positive tests compared
to serology (56%/61%) [20]. Fecal antigen was selected in
Fig. 1 Model structure for the Markov macrosimulation model for
studying a H. pylori screening interventions to reduce gastric cancer
in a population
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preference to urea breath test, because the former is
widely used in this setting and more affordable, despite
possible differences in acceptability.
Input parameters
Baseline parameters
The transition rate from ‘healthy’ to ‘gastric cancer’ was
governed by cancer registry incidence rates and varied
by ethnicity [21]. A 2% decline in gastric cancer inci-
dence over time was incorporated in the model, consist-
ent with global [5, 22] and New Zealand trends.
Mortality rates from other causes were obtained from
official New Zealand life tables [23], and the rates of
gastric cancer death were derived from New Zealand
cancer registry [24].
We used a modified version of a traditional quality-
adjusted life-year referred to as QALYDW. QALYsDW are
essentially the same as traditional QALYs, except in two
aspects: we use disability weights (rather than utilities)
derived using pairwise comparison methods in popula-
tion surveys from the Global Burden of Disease 2010
study [25], and we allow for sex and age-specific back-
ground morbidity from a New Zealand burden of disease
study [26]. We use the term QALYDW in the methods
sections of this paper, but default to “QALYs” elsewhere.
Effect size
A meta-analysis by Ford et al. [2] reported that the re-
duction in gastric cancer (referred to here as the effect
size) among people with H. pylori infection who were
treated vs not treated was 34% (RR: 0.66, CI: 0.46-0.95).
The effect size is only relevant to cases of gastric cancer
expected to occur in people with H. pylori infection that
is detected by screening. We therefore applied the effect
size to the number of gastric cancer cases that poten-
tially could be prevented i.e. non-cardia gastric cancer
that was attributable to H. pylori, for people who are
likely to be screened (i.e. coverage) and where H. pylori
is likely to be detected by the screening test (i.e. sensitiv-
ity of the screening test) (Table 1). We used these
specifications:.
1. The proportion of gastric cancer that was
non-cardia was set to the
New Zealand distribution of non-cardia and cardia
gastric cancer, excluding overlapping and undefined
subtypes (2007-2011 in New Zealand, Cancer
Trends). It varied by ethnicity and sex but was
generally stable by age.
2. We set 89% as the proportion of non-cardia gastric
cancer attributable to H. pylori (population attributable
fraction, PAF) [1], based on three prospective studies
from Europe and Australia, where H. pylori tested by
immunoblot was present in nearly 95% of non-cardia
gastric cancer cases [1]. It was not possible to allow the
PAF to vary by time and subgroup.
3. Coverage of screening in the main model was set
according to the coverage of cardiovascular risk
assessments (CVRA) for adults in New Zealand [27]
adjusted for primary care enrolment, namely 81% for
Māori and 84% for non-Māori. A scenario analysis
including ‘equal coverage’ by ethnicity was also run.
Both CVRA and H. pylori screening are administered
though primary care and involve blood tests in adults.
CVRAs are a funded government target.
4. The sensitivity of screening was set at 89% for
serology (and 95% for fecal antigen in a probabilistic
scenario analysis) in line with the literature [5, 28].
The effect size was modeled to respond to different
eradication rates by ethnicity, at least partially due to
differences in H. pylori clarithromycin resistance [29].
This was set using the relative eradication rate in New
Zealand [29] compared to a pooled eradication rate from
the meta-analysis (with the addition of 60% eradication
for people who failed first line therapy and were
retreated [16]).
In developing the model we assumed that the relative
risk reduction of gastric cancer in H. pylori positive par-
ticipants (largely dependent on one large trial in China)
[2] would be similar in high and low gastric cancer inci-
dence countries. The effect size was estimated to apply
over a lifetime of follow-up, similar to other cost-utility
analyses (CUAs; Table 3), and the reinfection rate in
screened adults was assumed to be 0% given transmis-
sion predominantly occurs in infants and children [5]. A
CUA in the UK that included a reinfection rate of 0.3%
in a scenario analysis, found it had a small impact on
cost-effectiveness [13].
It is plausible that the effect of treatment may be
greater in younger people because they have no pre-
existing metaplastic changes. However, a significant
effect size was evident in 55+ year olds in China [30]
and there was no statistical evidence from a meta-analysis
that the effect differed by presence of pre-neoplastic
lesions [2]. We therefore included all ages in this analysis,
assumed the effect size to be the same across age groups,
and suggest future trials and meta-analyses stratify results
by age wherever possible.
Costs
The downstream healthcare system costs and benefits that
were incurred or averted (offset) as a result of the interven-
tion were calculated from the health sector perspective.
Costs and benefits outside the health system such as bene-
fits to worker productivity were therefore out of scope.
Costs were reported in 2011 New Zealand dollars (NZ$)
and exclude a value-added tax (GST). Selected results are
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presented in United States dollars (US$) using the OECD
2011 purchasing power parity (2011: 1 NZ$ = 0.67 US$)
[31]. A 3% discount rate was applied to both costs and ben-
efits. Costs of the screening program were obtained from
current health system settings and adjusted to 2011 NZ$
using the New Zealand consumer price index [32].
The cost of publicly-funded health services by age was
from the New Zealand Ministry of Health database,
called ‘HealthTracker’. HealthTracker is a collection of
linked administrative datasets of publicly funded health
system events (including hospitalizations, mortality, cancer
registrations, mental health and addiction service use,










Meta-analysis rate ratio for incidence of gastric cancer in people with
H. pylori infection who were treated compared to untreatedb
Both: 0.66 (0.46–0.95)
Proportion gastric cancer that was non-cardia gastric cancer (2007-11)
Men 0.77 (0.69–0.85) 0.45 (0.41–0.49)
Women 0.89 (0.82–0.96) 0.63 (0.58–0.69)
Non-cardia gastric cancer where H. pylori infection is detectablea 0.89 (0.85–1.00)
Sensitivity of the serology test (Sesero) 0.89 [0.85–0.92] [28]
Expected coverage of serology test (using data from routine heart
and diabetes checks in NZ adults [27])a
0.81 (0.69–0.93)b 0.84 (0.72–0.97)b
Eradication rate reported by studies in the meta-analysis [2] 0.73 (0.71–0.75)
Eradication rate of OAC triple therapy in NZ, intention to treat [29]a 0.64 (0.53–0.75) 0.86 (0.75–0.96)
Eradication rate of OBTM quadruple therapy in NZ [16]a 0.7 [0.6–0.8]
Annual percentage decline in gastric cancer over time [5] 0.02 [0.01–0.03]
Screening pathway
H. pylori seroprevalence (proportion) by age-group (years) in 2011 [41]
25–29 0.11 [0.07–0.14] 0.08 [0.05–0.10]
30–34 0.15 [0.11–0.20] 0.10 [0.07–0.13]
35–39 0.20 [0.14–0.25] 0.13 [0.09–0.16]
40–44 0.24 [0.17–0.31] 0.15 [0.11–0.20]
45–49 0.29 [0.20–0.37] 0.18 [0.12–0.23]
50–54 0.33 [0.23–0.43] 0.20 [0.14–0.26]
55–59 0.38 [0.26–0.49] 0.23 [0.16–0.29]
60–64 0.42 [0.29–0.55] 0.25 [0.18–0.33]
65–69 0.47 [0.33–0.60] 0.28 [0.19–0.36]
Risk of Clostridium difficile infection post-treatment (Brown et al., 2013) 0.0008 [0.0004–0.0012]
Cost of hospitalization with moderate or severe C. difficile infection [34] $3,856 [3085–4628]
Costs of screening program (NZ, 2011)
(See Additional file 1: Table S2 for breakdown of costs and sources)
Cost per person invited (fixed health promotion, program costs) $39.87 [31.90–47.84]
Cost per person tested (test and result) $54.66 [43.73–65.59]
Cost per person with a positive test (GP visit, treatment, retest, complications) $176.70 [141.36–212.04]
Cost per person where eradication failed (GP visit, treatment, complications) $129.85 [103.88–155.82]
Confidence intervals (CI) (95%) and uncertainty ranges (also assumed to be 95%) were used to calculate standard deviations for uncertainty intervals (UIs) using a
Beta distribution for proportions and a normal distribution for scalars. There are also multiple baseline input parameters not included in this table (e.g. gastric
cancer rates by sex by age by ethnic group, competing background mortality rates and health system costs for a gastric cancer patient); see text
OAC omeprazole, amoxicillin and clarithromycin, OBTM omeprazole, bismuth/De-Nol, tetracycline and metronidazole, non-Māori includes Pacific, Asian, European
and Other ethnic groups
aContributes to the effect size and the screening pathway
bApplied the same standard error as for the OAC eradication rate
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pharmaceutical and laboratory claims, primary health
care enrolment, and outpatient/emergency department
visits) for the entire New Zealand population with unit
costs attached [33].
In the ‘healthy’ and ‘cancer’ states individuals were
assigned average population health system costs and aver-
age population morbidities. Additionally, in the “gastric
cancer” state individuals were assigned the excess costs of
gastric cancer. The average health systems costs in the last
year of life were assigned to those who died from other
causes and the excess cost of gastric cancer in the last year
of life was assigned to those who died from gastric cancer.
More information on costing is available in the Additional
file 1 and in study costing protocols [34, 35].
Screening program costs
For each strata of age, sex and ethnicity, the cost per
person screened was assigned based on fixed costs
applied to the total population invited to be screened,
costs per person tested, costs per expected rate of posi-
tive serology, and finally costs per positive retest (see
Additional file 1). Costs included patient co-payments
for primary care and pharmaceuticals.
Perhaps the most well-defined adverse effect of triple
therapy is the risk of Clostridium difficile infection (CDI)
with severe diarrhea. The cost of CDI was estimated as a
1–12 day hospital admission with severe diarrhea (using
cost weights for hospital events). We set the expected rate
of CDI at 80 per 100,000 people treated, according to an
estimated 11 per 100,000 incidence of CDI in the commu-
nity, and 2.65 times greater risk of CDI with macrolide
treatment and 2.71 times greater risk with penicillin [36].
The disability weight was not included in the model
because it was too small to affect QALYsDW gained given
that CDI is rare.
Analyses
Uncertainty analysis
Monte Carlo simulation techniques were used for prob-
abilistic sensitivity analysis to test the uncertainty in the
model outputs. This involved selecting key input parame-
ters probabilistically from their distributions using Excel
and Ersatz software (Table 1) with 2000 simulations.
Scenario analyses
Cost-effectiveness in the total population, and for Māori
and non-Māori subgroups, was examined deterministic-
ally for several scenarios including discounting, equity
analyses, low coverage, 15 years of follow-up, use of levo-




The H. pylori screening program cost was estimated
at NZ$24,600 ($11,300-$57,400) (US$16,500) per
QALY gained for the total population. The targeted
screening program for Māori was more cost-effective
at $11,985 ($5,719-$27,564) (US$8,030) per QALY
gained.
Compared to current practice, the total net cost of a
one-off total population H. pylori screening program for
25-69 year olds (with lifetime follow-up for downstream
health system costs) was $293 million (95% uncertainty
interval [UI]: $272-$314, probabilistic model, discount
rate 3%) (US$196 million) (Table 2). The net cost was
made up of $294 million ($282-$307) in intervention
costs, and $1.5 million (-$23-$26) due to downstream
future health system cost savings from reduced gastric
cancer incidence and associated treatment costs. In
comparison, a targeted H. pylori screening program (for
Māori only) had a net cost of a $41 million ($35-$46)
(US$27 million).
The health gain from the population screening program
was estimated at 14,200 QALYs (95% UI: 5100-26,300)
over the cohort’s lifetime. This corresponds to 3660
(1250–4430) fewer cases of gastric cancer, 2430 (830–
4430) averted deaths from gastric cancer, and a 17%
(6%–29%) reduction in the expected future gastric
cancer cases and deaths. The health gains for Māori
were greater per person with a 22% (7%–39%) reduc-
tion in the expected Māori gastric cancer incidence
and mortality.
For non-Māori, the cost per QALY was over twice that
for Māori at $29,600 per QALY gained ($13,400–$69,800)
(US$19,900). Within the non-Māori population there was
marked ethnic heterogeneity, with 15% who were Asian
and 7% who were Pacific (2013 census, 25–69 years old).
Pacific people have greater gastric cancer rates than Euro-
pean Other peoples.
Variation in cost-effectiveness by age was explored
for Māori and non-Māori subgroups (Fig. 2). Cost-
effectiveness for Māori was greatest in the 45–49 year
old age group and for non-Māori in the 60–64 age
group, likely due to relatively higher Māori rates of
gastric cancer at younger ages.
Compared to current practice, the fecal antigen test
was less cost-effective (ICER of $29,000 UI: $13,600-
$69,200 or $US 19,400) than serology-based screening
($24,600) (Table 2, Fig. 3). More specifically, the po-
tential QALYs gained with fecal antigen testing were
7.5% greater (15,300 vs 14,200 QALYs) but the cost
was 26% greater ($369 million vs $293 million). The
incremental cost-effectiveness of fecal antigen com-
pared to serology testing was $71,700 per QALY
gained.
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Table 2 Incremental costs, QALYs gained and ICERs for the total New Zealand adult population including a subset of the
population with high risk of gastric cancer (Māori), comparing serology and fecal antigen as the screening test, in 2011 with lifetime
follow-up of participants








Number cases of gastric cancer averted 3658 (1252–4425) 1007 (342–1828) 2650 (905–4837)
Percentage cases of gastric cancer averted 16.5% (5.6%–29.4%) 21.6% (7.4%–38.6%) 15.2% (5.2%–27%)
Number of gastric cancer deaths averted 2434 (834–4425) 714 (242–1293) 1720 (588–3141)
Percentage gastric cancer deaths averted 16.6% (5.7%–29.5%) 21.6% (7.3%–38.6%) 15.2% (5.2%–27%)
Total net incremental cost (NZ$ million) $293 ($272–$314) $41 ($35–$46) $252 ($233–$272)
Total intervention cost (NZ$ million) $294 ($282–$307) $41 ($38–$45) $253 ($242-$264)
Total cost offsets (NZ$ million) -$1.5 (-$26.2–$22.9) -$0.61 (-$7.35–$6.21) -$0.89 ($-22.7–$21.7)
Total QALYs gained 14,200 (5100–26,300) 4000 (1400–7400) 10,200 (3653–18974)
Incremental net cost per participant (NZ$) $119 ($111–$128) $137 ($117–$158) $117 ($108–$126)
Incremental QALYs gained per participant 0.0058 (0.0020–0.0107) 0.0137 (0.0047–0.0252) 0.0047 (0.0016–0.0087)
ICER (NZ$ per QALY gained) $24,600 ($11,300–$57,400) $12,000 ($5700–$27,600) $29,600 ($13,400–$69,800)
Men
Incremental cost per participant (NZ$) $123 ($113–$134) $147 ($123–$173) $120 ($110–$131)
Incremental QALYs gained per participant 0.0071 (0.0024–0.0131) 0.0158 (0.0055–0.0293) 0.0059 (0.0020–0.0110)
ICER (NZ$ per QALY gained) $20,800 ($9800–$47,900) $11,000 ($5600–$24,300) $24,300 ($11,300–$57,100)
Women
Incremental cost per participant (NZ$) $116 ($108–$124) $129 ($110–$148) $114 ($105–$123)
Incremental QALYs gained per participant 0.0046 (0.0016–0.0085) 0.0118 (0.0040–0.0217) 0.0036 (0.0012–0.0067)
ICER (NZ$ per QALY gained) $30,200 ($13, 400–$71,400) $13,200 ($5900–$31,300) $38,000 ($16,800–$89,900)
Fecal antigen based screening
Men and women
Total incremental cost (NZ$ million) $369 ($350–$389) $49 ($44–$55) $320 ($301–$339)
Total QALYs gained 15,300 (5400–27,700) 4200 (1500–7600) 11,000 (3830–20,200)
Incremental cost per participant (NZ$) $150 ($142–$158) $164 ($147–$182) $148 ($139–$156)
Incremental QALYs gained per participant 0.0061 (0.0022–0.0111) 0.0142 (0.0051–0.0259) 0.0050 (0.0018–0.0092)
ICER (NZ$ per QALY) $29,000 ($13,600–$65,900) $13,700 ($6700–$30,500) $34,900 ($16,300–$79,100)
Central estimates are the mean from the probabilistic sensitivity analysis Monte Carlo simulations and the brackets indicate the 95% uncertainty intervals
QALY quality-adjusted life year with disability weights, ICER incremental cost-effectiveness ratio
Fig. 2 Modeled cost-effectiveness of a H. pylori screening program in New Zealand by ethnicity, sex and age for the 25-69 year old population in
2011, expected value (deterministic analysis), NZ$ 2011. *See supporting documents for values on this graph
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Uncertainty analysis
Probabilistic sensitivity analysis demonstrated that at a
willingness-to-pay of NZ$45,000 per QALY, there was
greater than 99% probability that a serology-based screen-
ing program for Māori men and women would be cost-
effective. For non-Māori men and women the probability
was 94% and 77% respectively. The greatest contributor to
uncertainty in the model was the effect size of H. pylori
eradication (RR 0.66, 95% CI: 0.46-0.95) [2]. At the
extremes of the likely effect size, the cost-effectiveness of a
screening program for the total population was between
$12,000 and $58,200 per QALY gained.
Scenario analyses
Given the higher background mortality and morbidity
for Māori, a gastric cancer death prevented among
Māori typically achieves less health gain than a gastric
cancer death prevented among non-Māori (Table 3).
Therefore, we ran an ‘equity analysis’ where the Māori
analyses were rerun with non-Māori background mortal-
ity and morbidity rates. This resulted in a 36% increase
in QALYs (Table 3). In an equal coverage scenario
Māori analyses were rerun with non-Māori coverage,
resulting in 4% greater QALY gains for Māori. When
analyses were rerun with low screening coverage
adopting participation rates from the first year of a
colorectal screening pilot program in one New Zealand
health district (Waitemata), the QALY gains were 40% less
for Māori and 30% less for total population.
The screening program was considerably less cost-
effective when the treatment effect was applied for a
limited follow-up period of 15 years (ICER was 73%
greater; the maximum follow-up in the most relevant
meta-analysis was 15 years). Discounting (costs and
benefits) had a large impact on cost-effectiveness (par-
ticularly on QALYs) reducing the ICER by 50% with no
discounting; and increasing the ICER by 90% for 6%
discounting. Substituting a lower screening coverage in
the model (45% for Māori and 58% for non-Māori)
caused the ICER to increase by 19% (Table 3).
Discussion
Main findings and interpretation
In this analysis from a high income country, the cost-
effectiveness of targeted screening in a high gastric
cancer incidence group (Māori ICER $12,000, UI
$5,700–$27,600) was more favorable than for the total
population (ICER $24,600, UI $11,300–$57,400). These
findings are analogous to US findings where cost-
effectiveness of screening was better for Japanese American
and African American participants [8, 17].
Our results for the non-Māori group (ICER of
NZ$24,700, expected deterministic result, Table 3) include
populations with low and high gastric cancer rates (such
as Pacific peoples). Whilst we did not have data for a full
ethnicity-disaggregated model, if we assume that the inter-
vention costs are distributed pro-rata by population
counts, and that the health gain is distributed proportional
to gastric cancer incidence (2007–2011), then we roughly
estimate that the cost-effectiveness would be $8,300 for
Pacific (76% less than non-Māori altogether), $29,000 for
Asian and $28,800 for European/Other (both the later
were 17% greater than non-Māori aggregated). These esti-
mates are very approximate however and do not allow for
Fig. 3 Incremental costs and QALYs gained from a H. pylori screening program for Māori and the total population, comparing serology versus
fecal antigen screening tests
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different age structures, different background mortality
and morbidity rates, and heterogeneity within the Asian
group. At this level of cost-effectiveness for European/
Other the uncertainty in treatment effect size and differ-
ences in cost-effectiveness by age and sex become particu-
larly relevant to decision makers. We conclude that H.
pylori screening is probably of borderline cost effectiveness
for European/Other, but probably cost-effective for Pacific
people as well as Māori.
Variation in results by age and sex reflect the epidemi-
ology of non-cardia gastric cancer. The intervention was
particularly more cost-effective in younger Māori adults
(45–49 year olds). Among Māori cost-effectiveness was
similar in men and women, consistent with findings
from a high risk region of China [19]. In non-Māori,
cost-effectiveness peaked in participants aged 60–64
years old similar to studies in the UK [13] and US [7];
and H. pylori screening was more cost-effective in men,
similar to US findings [17].
Serology based screening was more cost-effective than
fecal antigen based screening (Fig. 3). The incremental
cost effectiveness of moving from serology to the fecal
antigen test was $71,700 per QALY gained. Although the
fecal antigen test has a preferable sensitivity (95% vs
89%) and is likely to result in greater health gains, the
cost of the test was problematic (fecal antigen test cost
was $65.20 vs $30.68 for serology). Reduction in the cost
of fecal antigen testing would shift the balance towards
making fecal antigen based screening more cost-effective
than serology. The fecal antigen test is widely used in
many high-income countries, and there may be potential
to introduce it in combination within a country’s
national colorectal screening program (if differences in
stool sample requirements can be addressed). Fecal anti-
gen may however adversely impact on screening uptake
given likely participant dislike of dealing with fecal mater-
ial. Conversely, H. pylori serology could be added onto
existing blood test requests in primary care as part of the
routine screening for other conditions (such as diabetes
and cardiovascular risk in the New Zealand case).
Strengths and limitations
The key strengths of this CUA are the adoption of a re-
cent meta-analysis effect size for H. pylori eradication
[2], presenting incremental costs per QALY gained, using
probabilistic sensitivity analysis, and allowing for adverse
effects of treatment costs (CDI). Our input variables in-
cluded high quality New Zealand ethnicity, cancer regis-
tration and cost data. Meta-analysis results from high
risk populations [2] were shaped to fit the New Zealand
context by taking into account differences in non-cardia
gastric cancer incidence, the PAF for H. pylori and
gastric cancer [1], New Zealand eradication rates for H.
pylori treatment [29], and the declining incidence of
Table 3 Scenario analyses and their impact on health gain, health system costs, and incremental cost-effectiveness ratios per person
screened, New Zealand dollars 2011
Incremental costs (NZ$) Incremental QALYs gained Incremental cost-effectiveness ratio
Total Māori Non-Māori Total Māori Non-Māori Total Māori Non-Māori
Main modela $119 $138 $117 0.006 0.014 0.005 $20,600 $10,100 $24,700
Equity analysis—equal life expectancy and background
morbidity for Māori and non-Māori
$121 $155 $117 0.006 0.019 0.005 $18,800 $8,200 $24,700
Equal coverage—coverage in Māori was set to the same
as non-Māori (84%)
$120 $143 $117 0.006 0.014 0.005 $20,400 $10,000 $24,700
Low coverage—coverage in Māori of 45% and non-Māori
of 58% akin to a NZ colorectal screening pilot
$93 $95 $93 0.004 0.008 0.003 $24,500 $12,400 $28,400
Equal eradication—triple therapy was increased to be 95%
effective (e.g. levofloxacin)
$118 $132 $116 0.006 0.015 0.005 $19,600 $8,900 $24,200
No retest to ensure effective eradication $101 $107 $100 0.005 0.010 0.004 $20,600 $10,900 $23,600
Follow-up for 15 years (rather than over a lifetime) $118 $132 $116 0.003 0.008 0.003 $35,600 $16,000 $44,000
The effect size in the youngest age groups is greater
(<40yo, RR of 0.50)
$119 $139 $117 0.006 0.016 0.005 $18,400 $8,700 $22,500
The complication rate for CDI was increased from
80 to 800 per 100,000
$124 $146 $121 0.006 0.014 0.005 $21,400 $10,700 $25,600
6% discounting QALYs and costs $112 $118 $111 0.003 0.007 0.002 $39,200 $17,300 $48,200
0% discounting QALYs and costs $151 $225 $141 0.015 0.034 0.012 $10,300 $6,600 $11,700
No unrelated health system costs $82 $52 $86 0.006 0.014 0.005 $14,200 $3,800 $18,300
No pYLDs (background morbidity) $119 $138 $117 0.008 0.021 0.007 $14,300 $6,700 $17,500
Deterministic results were used in the sensitivity analysis for efficiency and differ slightly from probabilistic results
aMain model includes 3% discounting of both QALYs and costs
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gastric cancer. We compared results by age, sex and
ethnicity including for a population with relatively high
rates of gastric cancer (Māori).
Nevertheless, the modeled benefits of our screening
program are likely to be underestimated as we did not
have the primary care data to include the health gains
and cost reduction benefits from reduced dyspepsia and
peptic ulcers attributable to H. pylori infection in this
context. However, screening studies in the UK have
demonstrated a 25% reduction in dyspepsia after two
years of follow-up, with a mean saving of dyspepsia-
related costs of US$117 per person ($11–$220) in the
10 years after eradication therapy [37]. If this cost-saving
from dyspepsia was the same in the New Zealand con-
text, cost-effectiveness may be greater in our model. For
example, if we used UK dyspepsia-related cost-savings,
and subtracted these from the model’s costs in 45-49
year olds seropositive for H. pylori over a ten year time
line, this would reduce the ICER by an estimated 24% in
Māori and 20% in European/Other, even when not
considering the likely QALY gain from dyspepsia relief
(see Additional file 1: Table S8 for this calculation). Fur-
thermore, other than CDI, we were unable to account for
potential harms from H. pylori eradication treatment how-
ever adverse effects are often rare and inclusion is unlikely
to influence our findings. Similarly, we did not account for
any increased anxiety among those screened and told that
they have H. pylori infection (or the reassurance value
when told that they are free of infection).
This CUA was based on H. pylori prevalence and gastric
cancer incidence in New Zealand for 2011 in all ages from
25 to 69 years. Cost-effectiveness may gradually decrease
over time as H. pylori prevalence and gastric cancer inci-
dence decline. It will take several decades however for the
current high risk birth cohorts to be replaced by younger
cohorts at low risk of H. pylori infection. H. pylori screen-
ing in populations with high gastric cancer incidence such
as Māori appears likely to remain cost-effective for some
decades into the future. Cost-effectiveness also depends
on which age group is screened.
Furthermore, positive serology does not represent an ac-
tive infection and some participants are likely to be treated
without having H. pylori in their stomach. This could
be remedied somewhat by using a fecal antigen test in-
stead (as modelled) or the more expensive options of a
urea breath test or a two-way diagnostic procedure.
The latter would have a greater chance of losing people
over two steps. Also if participants are not tested after
a second therapeutic attempt a small proportion (3–
4%) may still have H. pylori infection. To avoid falsely
reassuring treated individuals, information materials
should state that treatment is not 100% effective and if
they get gastric symptoms in the future they should
consult their doctor.
Practice, policy and research
The WHO recommends that countries should consider
piloting H. pylori screening to evaluate its impact on
gastric cancer, all-cause mortality and potential adverse
effects [5]. Given current evidence, our results indicate
that screening and treating definable ethnic groups with
a high risk of developing gastric cancer is likely to be the
most cost-effective approach in high-income country
settings. Screening may also be cost-effective in popula-
tions with low incidence of gastric cancer but more
evidence is probably needed to establish more precise
estimates of screening benefits and costs by age, sex and
risk status.
There are many other factors that should be considered
before the introduction of screening programs [38]. More
information is required about the balance of harms and
benefits of screening, the acceptability and feasibility of H.
pylori infection screening tests, the capacity of the health
care system particularly primary care, and potential ethical
issues about identifying infection and being unable to treat
it in some cases. Policy-makers would also need to con-
sider the relative cost-effectiveness and potential equity
gains of alternative interventions in high-income countries
such as tobacco control, obesity control and other screen-
ing programs (for example colorectal cancer, chronic
kidney disease and lung cancer in ex-smokers).
Trials of population based H. pylori screening in
participants as young as 25 years and up to 69 years,
are under way in Linqu Country, China; United Kingdom;
Matsu Islands in Taiwan; Korea and another is planned for
Latvia, Belarus and the Russian Federation [39]. Emerging
evidence should be actively monitored to clarify the poten-
tial adverse effects of H. pylori screening and treatment
(such as all-cause mortality outcomes from screening
trials), and the most effective models of implementa-
tion. Potential adverse effects from H. pylori treatment
require further evaluation since confounding is a likely
contributor to inverse associations demonstrated between
H. pylori infection and esophageal cancer, asthma, ischemic
heart disease, colon cancer and antibiotic resistance [40].
Nevertheless, given what is known to date it would seem
reasonable for policy-makers in high-income countries to
start exploring the option of pilot screening programs for
H. pylori, especially in population groups with relatively
high rates of gastric cancer.
Conclusions
This CUA modeling study found that a H. pylori screening
program was cost-effective in this high-income country
setting for the indigenous Māori population (and likely by
extension to Pacific peoples). The program was of likely
borderline cost-effectiveness for the European/Other
population. A screening program may therefore help to
address the existing inequalities in the burden of gastric
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cancer. While further research will help clarify the precise
benefits, costs and adverse effects of such screening pro-
grams, there seems a reasonable case for policy-makers to
give consideration to establishing pilot programs now,
particularly for any population groups with relatively ele-
vated rates of gastric cancer.
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